New Data from KEYNOTE-028, Merck ’s Trial Evaluating KEYTRUDA® (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Findings Show Anti-Tumor Activity for KEYTRUDA in Two Gastrointestinal Cancers < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new findings from the KEYNOTE-028 Phase 1b study, the
clinical trial investigating the use of the company ’s anti-PD-1 therapy,
KEYTRUDA < sup > ® < /sup > (pembrolizumab) in multiple, difficult-to-treat
cancers. Data from this trial, to be presented at the European Cancer
Congress (ECC) in Vienna, Austria, Sept. < /p > < div class= " field field-type-text field-field-press-release-language field-fieldpressreleaselanguage " > < div class= " field-label " > Language: < /div > < div class= " field-items " > < div class= " field-item odd " >
English < /div > < /div > < /div > < div class= " field field-type-text field-field-press-releas...

Source: Merck.com - Product News - September 27, 2015 Category: Drugs & Pharmacology Tags: Oncology Newsroom Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news